Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia (NCT02162420) | Clinical Trial Compass
CompletedNot Applicable
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
United States61 participantsStarted 2015-01-10
Plain-language summary
Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.
Who can participate
Age range0 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 0 - 70 years
* Acceptable hematopoeitic stem cell donor
* Dyskeratosis Congenita (DC) with evidence of BM failure defined as:
* requirement for red blood cell and/or platelet transfusions or
* requirement for G-CSF or GM-CSF or erythropoietin or
* refractory cytopenias having one of the following three
* platelets \<50,000/uL or transfusion dependent
* absolute neutrophil count \<500/uL without hematopoietic growth factor support
* hemoglobin \<9g/uL or transfusion dependent
* Diagnosis of DC with a triad of mucocutaneous features:
* oral leukoplakia
* nail dystrophy
* abnormal reticular skin hyperpigmentation, or
* Diagnosis of DC with one of the following:
* short telomeres (under a research study)
* mutation in telomerase holoenzyme (DKC1, TERT, TERC, NOP10, NHP2, TCAB1)
* mutation in shelterin complex (TINF2)
* mutation in telomere-capping complex (CTC1)
* Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:
* Refractory cytopenia defined by bone marrow cellularity \<50% (with \< 30% residual hematopoietic cells)
* Diagnosis of SAA with refractory cytopenias having one of the following three:
* platelets \<20,000/uL or transfusion dependent
* absolute neutrophil count \<500/uL without hematopoietic growth factor support
* absolute reticulocyte count \<20,000/uL
* Severe Aplastic Anemia (SAA) requiring a 2nd transplant
* Graft failure as defined by blood/marrow chimerism of…
What they're measuring
1
Incidence of Neutrophil Engraftment
Timeframe: Day 42
2
Incidence of Platelet Engraftment
Timeframe: 1 year
Trial details
NCT IDNCT02162420
SponsorMasonic Cancer Center, University of Minnesota